Genmab/Abbvie's Epcoritamab Achieves a 100% Response Rate In Patients With R/R F

1. Genmab/Abbvie's Epcoritamab Achieves a 100% Response Rate In Patients With R/R Follicular Lymphoma The efficacy and safety data for epcoritamab will be presented by Genmab and Abbvie. What is the market position of the antibody in Florida? EPCORE NHL-2 is a Phase Ib/II study in R/R FL that looks at the safety and preliminary efficacy of epcoritamab in combination with other drugs. Epcoritamab is an experimental IgG1-bispecific antibody developed with Genmab's unique DuoBody technology that is currently being tested in numerous clinical trials as a therapy option for individuals with FL. In March 2022, Genmab reported that epcoritamab had been granted Orphan Drug Designation by the US Food and Drug Administration for the treatment of FL. In April 2022, Roche stated that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) had recommended approval of mosunetuzumab in R/R FL

2. patients who had received at least two prior systemic therapy under conditional marketing authorization. The European Commission is likely to make a final judgement on mosunetuzumab conditional approval soon, based on this positive CHMP view. In June 2020, mosunetuzumab was granted Breakthrough Therapy Designation by the US FDA 2L+ FL patients. The CHMP recommendation was based on positive results from the Phase I/II study, where mosunetuzumab showed high complete response (CR) rates, with most complete responders maintaining responses for at least 18 months and favorable tolerability in people with heavily pretreated FL. In addition to that, after a median follow-up of 18.3 months, the CR rate was 60% (n = 54/90), the objective response rate was 80% (n = 72/90), and the median progression-free survival was 17.9 months. The median duration of response among those who responded was 22.8 months. Therefore, we are inquisitive about the presentation concerning these bispecific antibodies on June 4, 2022, at the ASCO 2022 Conference via Poster Session. Abstract Number – 7510 BTK inhibitor from Beigene in patients with high-risk follicular lymphoma. In patients with R/R non-follicular Hodgkin's lymphoma, ROSEWOOD is a global Phase II trial comparing the effectiveness, safety, and tolerability of BGB-3111 (zanubrutinib) plus obinutuzumab versus obinutuzumab alone. Brukinsa, one of Beigene's most well-known drugs, is a Bruton's tyrosine kinase (BTK) inhibitor that is now being tested in a variety of B-cell malignancies around the world. Mantle cell lymphoma, marginal zone lymphoma, and Waldenström's macroglobulinemia are among the diseases for which the company has already received approval in Latin America. In addition, the company is broadening its horizons to include new indications. Imbruvica is a prominent competitor for Brukinsa in the BTK inhibitor class (Ibrutinib). We anticipate hearing positive results from the ROSEWOOD trial in Florida at the ASCO 2022 Conference through Poster Discussion Session on June 5, 2022. Conclusion For R/R FL, there is no conventional treatment or treatment sequence. As a result, the projected outcomes of bispecific antibodies could be an enhancer in terms of treatment strategies for follicular lymphoma patients. Because the majority of persons with follicular lymphoma have frequent relapses, the duration of remission and survival shortens with each subsequent therapy. In the case of hematologic malignancies, this could provide patients new hope for therapeutic alternatives. The contest between epcoritamab and mosunetuzumab has piqued curiosity, given that mosunetuzumab will have a first-mover advantage, as the business has finished the European filing process and CHMP has already validated their MAA application. As a result, we anticipate positive results from these bispecific antibodies in FL

3. If authorized, Mosunetuzumab would be the first CD20xCD3 T-cell engaging bispecific antibody accessible to treat FL, providing a new fixed-duration, off-the-shelf therapeutic option. BTK inhibitors are also intriguing new treatments with potential efficacy in B-cell malignancies, but response rates were slightly lower in several indications, such as DLBCL, FL, and MM. The primary analysis of the ROSEWOOD trial, on the other hand, was expected to yield useful insights and open new vistas for patients with follicular lymphoma. Furthermore, CAR-T cell treatments are more effective in the treatment of DLBCL, FL, and other hematologic malignancies. The recent FDA and EC approval of Novartis' Kymriah as the first CAR-T cell treatment for adults with R/R FL supports this theory. In a word, we anticipate that CAR-T cell treatments will pose a significant threat to bispecific and monoclonal antibodies. To Get a Detailed analysis of ASCO Conference 2022 Abstracts, Visit: ASCO 2022 Detailed Coverage | ASCO Conference | ASCO Conference 2022 | ASCO Abstract 2022 Some of the Latest ASCO Abstract 2022 Launched: Can Breyanzi be a hit CAR-T in second-line treatment after failing in the first-line setting for the patients with R/R Large B-cell lymphoma (LBCL)? Teclistamab, a soon-to-be-approved bispecific antibody, demonstrates its promise in Multiple Myeloma during ASCO 2022. Merus’ Zenocutuzumab, a HER2-HER3 Bispecific Antibody, Successfully Targets NRG1 Fusions in Lung and Pancreatic Cancer Trending & Popular Healthcare Research Reports 2022 by Delveinsight Plaque Modification Devices Market DelveInsight’s ‘Plaque Modification Devices -Market Insights, Competitive Landscape and Market Forecast - 2027’ report delivers an in-depth understanding of Plaque Modification Devices Chronic smell and flavor loss Market DelveInsight's Chronic smell and flavor loss Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Chronic smell and flavor Facial Lines Market DelveInsight's Facial Lines Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Facial Lines, historical and forecasted epidemiology Metastatic Castration-Resistant Prostate Cancer Market DelveInsight's Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the

4. Metastatic Castration-Resistant Prostate Cancer (mCRPC), historical and forecasted epidemiology as well as the Metastatic Castration-Resistant Prostate Cancer (mCRPC) market trends in 7MM. Sarcopenia Market DelveInsight's Sarcopenia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sarcopenia, historical and forecasted epidemiology. Paranasal Sinus Cancer Market Paranasal Sinus Cancer Market Insights, Epidemiology, Market Forecast report delivers an in- depth understanding of the Paranasal Sinus Cancer epidemiology. Medical Marijuana Market DelveInsight’s Medical Marijuana Market Insights, Epidemiology and Market Forecast - 2032 report provides the detailed overview of the disease and in depth understanding of historical. Stem Cell Market Stem Cell Market Research Report provides comprehensive insights into the Stem Cell Market Size, Share, Key Companies, Competitive Analysis as well as the Market Forecast Proteus Syndrome Market Proteus Syndrome Market Insights, Epidemiology, and Market Forecast-2032 report delivers an in-depth understanding of the Proteus Syndrome, historical and forecasted epidemiology. Inflammatory Pain Market Inflammatory Pain Market Insights, Epidemiology, and Market Forecast-2032 report deliver an understanding of the forecasted epidemiology, and the Inflammatory Pain market trends in 7MM. Shigellosis Market DelveInsight's Shigellosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Shigellosis, historical and forecasted epidemiology Asperger Syndrome Market DelveInsight's Asperger Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Asperger Syndrome market trends in 7MM. Trending & Popular Healthcare Research Reports B Cell Chronic Lymphocytic Leukemia Market Medical Marijuana Market

5. Opioid-related Disorders Market Polycystic Kidney Disease Market UK Healthcare Outlook Report Urinary Catheters Market Coronary Microvascular Dysfunction CMD Market Sick Sinus Syndrome Market Oncolytic Virus Cancer Therapy Pipeline Pelvic Organ Prolapse Market B-Cell Maturation Antigen Targeted Therapies Market Asperger Syndrome Market Tuberculosis Market Sly Syndrome Market Membranous Nephropathy Market Proteus Syndrome Market About Us DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions. Contact Us Yash info@delveinsight.com